The preparation of phenylalanyl-tRNA terminating in 3'-deoxyadenosine has been achieved by incubation of abbreviated tRNA (tRNA-CpCoH) with 3
tidyltransferase reaction. Neither of the modified tRNAs acted as a donor in the peptidyltransferase reaction.
Considerable interest has developed recently in a description of the structures of the aminoacyl-and peptidyl-tRNAs that are formed and utilized enzymatically during the several stages of protein biosynthesis. Central to this concern is the nature of the aminoacyl (peptidyl) linkage with the adenosine moiety at the 3'-end of the tRNA. Since the amino acid may form an activated ester with either the 2'-or 3'-hydroxyl group of the adenosine moiety, and may equilibrate rapidly between the two forms by way of an orthoester which may itself represent an energy minimum, a description of the position and conformation of the amino acid at each step of protein biosynthesis has been difficult to realize.
A promising approach to the solution of this problem has involved utilization of analogs of the adenylate portion of tRNA, and especially of tRNA itself. It has been shown, e.g., that tRNAs terminating in 3'-deoxyadenosine or 3'-amino-3'-deoxyadenosine, but not 2'-deoxyadenosine, can be aminoacylated enzymatically (1) (2) (3) (4) , while tRNAs terminating in 2'-O-methyladenosine or 3'-O-methyladenosine are at best poor substrates for aminoacyl-tRNA synthetase (5) . A description of the structures of the aminoacyl-and peptidyltRNAs that participate in subsequent steps of the overall protein synthesis process has been inaccessible, however, because the specificity of the aminoacyl-tRNA synthetase has precluded the construction of an isomeric pair of aminoacyltRNAs terminating, e.g., in 2'-and 3'-deoxyadenosine. This report is concerned with the construction of isomeric phenylalanyl-tRNAPhe analogs terminating in 2'-deoxy-3'-O-phenylalanyladenosine and 3'-deoxy-2'-O-phenylalanyladenosine, with their chemical conversion to the corresponding Nacetylphenylalanyl-tRNA Phes, and with the utilization of these species in assays that define more exactly the structural requirements for certain steps in the overall process of protein biosynthesis with respect to the aminoacyl (peptidyl) moiety of the tRNA.
MATERIALS AND METHODS
Cordycepin, RNase- 3'-Deoxyadenosine was phosphorylated with pyrophosphoryl chloride (7), tritiated (8) , and subsequently converted to 3'-[3H]deoxyadenosine 5'-diphosphate (9) . Tritiated 3'-O-(N-carbobenzyloxy-L-phenylalanyl)-2'-deoxyadenosine 5'-diphosphate was prepared by treatment of 2'-deoxyadenosine 5'-diphosphate with the imidazolidate of tritiated N-carbobenzyloxy-L-phenylalanine (10 (12) . Preparation of tRNAs Terminating in 2'-and 3'-O-Methyladenosine. These tRNAs were prepared as described (5) These tRNAs were purified by periodate oxidation of the vicinal glycol moieties in the remaining abbreviated tRNAs, followed by chromatography on aminoethylcellulose to afford purified, unfractionated tRNA analogs 2-5. Attempted Transfer of N-Acetyl-L-phenylalanine from Modified N-Acetyl-L-phenylalanyl-tRNAs to L-[3H]phenylalanyltRNA. N-Acetyl derivatives of the modified phenylalanyltRNAs were prepared as described (13 steps on BD-cellulose and RPC-5. Species 3 was then aminoacylated enzymatically with L-phenylalanine. In this fashion the isomeric, aminoacylated tRNA analogs 7a and 8a were obtained and these were compared for function with phenylalanyl-tRNAPhe (analog 6a). Because tRNA species 7a had a specific activity of only 1.8 Ci/mol, the ribosomal A-site and P-site binding affinities of analogs 7 and 8 were determined from competition experiments in which they were used as potential inhibitors of the binding of unmodified (N-acetyl)
[aH]phenylalanyl-tRNAPhe. As indicated in Table 2 , the EF-Tu-dependent binding of [SH phenylalanyl-tRNAPhe to the ribosomal A-site in response to poly(U) was inhibited equally as well by equimolar amounts of tRNA species 7a or 8a, or by unlabeled phenylalanyltRNAPhe (analog 6a). In contrast, neither unaminoacylated tRNAPhe nor tRNAs terminating in 2'-deoxyadenosine (analog 2) or 3'-deoxyadenosine (analog 3) were nearly as inhibitory to the binding of [3Hlphenylalanyl-tRNAPhe as were analogs 6a-8a. These competition experiments were Table 4 ).
Transfer RNA species 6a-8a were converted chemically to their corresponding N-acetyl derivatives (analogs 6b-8b) and assayed for their ability to inhibit the binding of N-acetyl-i-[8H ]phenylalanyl-tRNAPhe to the ribosomal P-site. The results of this experiment are recorded in Table 3 . Neither species 7b nor 8b competed for the P-site as efficiently as N-acetyl-L-phenylalanyl-tRNAPhe (analog 6b) (36% and 35%, respectively, compared with 50%) when assayed in equimolar concentration with N-[3H]acetylphenylalanyl-tRNAPhe, although all were significantly better as inhibitors of N-['H]acetylphenylalanyl-tRNAPh, binding than the aminoacylated (analogs 6a-8a) or unaminoacylated (analogs 1-3) tRNAs.
The activities of the phenylalanyl-tRNAs (analogs 6a-8a) and N-acetylphenylalanyl-tRNAs (analogs 6-S8b) were also measured as acceptors and donors, respectively, in the peptidyltransferase reaction. The results of the attempted transfer of N-[8H]acetylphenylalaniDe from N-[8H]acetylphenylalanyl-tRNA to each of the i-phenylalanyl-tRNAs (analogs 6a-8a) are given in Table 4 . Under conditions that resulted in the binding of 28% of added N-acetyl-r.-['H]-phenylalanyl-tRNAPhe to the ribosomal P-site, the further addition of phenylalanyl-tRNAPhe (analog 6a) to the assay system resulted in transfer of 70% of the bound counts to phenylalanyl-tRNA. Under the same conditions, the addition of species 7a to an assay system containing N-['H]acetylphenylalanyl-tRNAPhe prebound to the P-site resulted in the transfer of 17% of the bound counts, while the addition of aminoacyl-tRNA species 8a resulted in no transfer, relative to a control to which no aminoacyl-tRNA was added. In the complementary experiment, 74% of the N-acetylphenylalanyl-tRNAPhe (analog 6b) prebound to the ribosomal P-site Although the tRNA terminating in 2'-deoxy-3'-0-phenylalanyladenosine (analog 7a) was not accessible by enzymatic aminoacylation, it was constructed successfully by a novbl procedure involving the addition to the tRNA of 2'-deoxy-3'-O-phenylalanyladenosine 5'-monophosphate by the action of polynucleotide phosphorylase on 2'-deoxy-3'-O-phenylalanyladenosine 5'-diphosphate and abbreviated tRNA (tRNA-CPCOH). This approach was suggested by the work of Kaufmann and Littauer (15) , who used the enzyme successfully in the reverse reaction to obtain aminoacyladenosine 5'-diphosphates from aminoacylated tRNA. The successful construction of the isomeric phenylalanyl-tRNAPhe species 7a and 8a permitted a direct comparison of their activities at the various stages of protein biosynthesis. Both species, for example, exhibited the same EF-Tu-dependent A-site binding affinity in response to poly(U) as did unmodified phenylalanyltRNAPhe, in agreement with conclusions reached from studies of single isomers of modified tRNA species (3). Also in agreement with published work (4, 14) was the finding that only species 7a was an acceptor in the peptidyltransferase reaction, although the extent of transfer was considerably less than that achieved with unmodified phenylalanyl-tRNAPhe. Binding of tRNA species 6b-8b to the ribosomal P-site was measured in terms of the ability of each unlabeled species to inhibit the binding of N-[3H]acetylphenylalanyl-tRNA. Modified species 7b and 8b were of equal activity in the assay and were better inhibitors than the unacetylated phenylalanyl-tRNAs (analogs 6a-8a). However, neither species was as inhibitory as unmodified N-acetylphenylalanyl-tRNAPhe (analog 6b). Significantly, neither species 7b nor 8b was active as a donor in the peptidyltransferase assay.
Several workers have suggested that the lack of protein synthesis promoted by modified tRNAs (e.g., species 8a) was due not to insufficient activation of the aminoacyl moiety in these species, but rather to their inability to isomerize to the alternate positional isomer, which might be required during protein synthesis. The construction of aminoacyl-tRNAs terminating both in 2'-and 3'-deoxyadenosine (analogs 7a and 8a) has permitted us to show that this is not the case. The tRNA terminating -in 3'-deoxyadenosine was aminoacylated to the same extent and almost as quickly as unmodified tRNA, indicating little contribution from the vicinal hydroxyl group in the aminoacylation process. The corresponding tRNA terminating in 3'-O-methyladenosine, however, was aminoacylated only about 7% as well as unmodified tRNA, suggesting a stringent steric requirement in this reaction. Although both species 7a and 8a were bound to the ribosomal A-site as well as unmodified tRNA, neither species 7b nor 8b was bound to the P-site as well. This suggested a lack of specificity for a particular positional isomer in the binding reactions, but some contribution from the vicinal hydroxyl group in P-site binding. Furthermore, although analog 7a was an acceptor in the peptidyltransferase reaction, it had little activity relative to the normal substrate and neither of the acetylated analogs (7b or 8b) had any activity as peptide donors. This again indicated the need for a vicinal hydroxyl group in functional aminoacyl-and peptidyl-tRNAs.
In agreement with other workers, we believe that tRNA is normally aminoacylated on the 2'-hydroxyl group of the terminal adenosine moiety and isomerizes to afford a tRNA terminating in 3'-aminoacyladeenosine before acting as an acceptor in the peptidyltransferase reaction. On the basis of our experiments we also conclude that at least for tRNAPhe, and presumably for others as well, there is no positional requirement for the aminoacyl or peptidyl moiety in A-site or P-site binding. However, contrary to the suggestions of others, we conclude that the modified tRNAs fail to participate in protein synthesis simply because they are inadequate analogs of aminoacyl-tRNA with respect to P-site binding, as well as acceptance and donation in the peptidyltransferase reaction.
